CG Oncology CFO Robert Lapetina resigns; Jim DeTore named interim CFO effective Nov 17, 2025

CG Oncology, Inc.

Robert Lapetina resigned as interim principal financial and accounting officer, effective Nov 30, 2025.
Jim DeTore appointed interim principal financial and accounting officer, effective Nov 17, 2025, via consulting agreement with Monomoy Advisors.
DeTore to receive $32K for November (prorated) and $64K/month thereafter; initial term min 3 months, extendable 3 months.
DeTore previously CFO at Neurogastrx (2021-2025) and Bluebird Bio (2014-2016); independent consultant 2017-2021.
No family relationships or conflicts disclosed; DeTore eligible for standard indemnification agreement.

item 5.02

Machine-readable event card

schema_version: secwatch.filing_event.v1
accession: 0001193125-25-283108
form_type: 8-K
ticker: CGON
cik: 0001991792
company_name: CG Oncology, Inc.
filed_at: 2025-11-14T23:59:59+00:00
discovered_at: 2026-05-14T18:02:41.227171+00:00
generated_at: 2026-05-16T19:57:08.839963+00:00
sec_items: ["5.02"]
event_type: leadership
sentiment: neutral
materiality_score: 0.3
confidence: high
secwatch_canonical_url: https://secwatch.observer/filing/0001193125-25-283108
json_url: https://secwatch.observer/filing/0001193125-25-283108.json
markdown_url: https://secwatch.observer/filing/0001193125-25-283108.md
text_url: https://secwatch.observer/filing/0001193125-25-283108.txt
edgar_index_url: https://www.sec.gov/Archives/edgar/data/1991792/000119312525283108/0001193125-25-283108-index.htm
edgar_primary_document_url: https://www.sec.gov/Archives/edgar/data/1991792/000119312525283108/ck0001991792-20251110.htm
generated_by_model: deepseek-v4-flash:cloud@v2
review_status: machine_generated
human_reviewed: false
corrected: false
correction_note: null
correction_timestamp: null
superseded_by: null

JSON Markdown Plain text

Source: SEC EDGAR

accession 0001193125-25-283108

view filing index on sec.gov

view primary document

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.